Five hospitals in England and Wales have switched to urine test, rather than invasive hospital procedure ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

In a multi-institutional study published in the European Urology journal, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher ...

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The ...

Marks the first Medicare coverage decision for Veracyte’s whole-genome sequencing-based TrueMRD platform and launch of the first test Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics ...

Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...